Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized Study to Assess the Safety and Anti-cytomegalovirus (CMV) Activity of Different Doses of Maribavir for Treatment of CMV Infections That Are Resistant or Refractory to Treatment With Ganciclovir/Valganciclovir or Foscarnet in Transplant Recipients

NCT01611974 is registered in ClinicalTrials.gov with Shire as lead sponsor.

NCT NCT01611974
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01611974 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized Study to Assess the Safety and Anti-cytomegalovirus (CMV) Activity of Different Doses of Maribavir for Treatment of CMV Infections That Are Resistant or Refractory to Treatment With Ganciclovir/Valganciclovir or Foscarnet in Transplant Recipients
Lead sponsor
Shire
Phase
Phase 2
Overall status
Completed
Start date
July 17, 2012
Completion date
December 5, 2014
Enrollment
120 (actual)
Sites
32

Conditions

As the registry lists them; a condition with its own page is linked.

cytomegalovirus (cmv)